Patents Assigned to Juno Therapeutics GmbH
-
Publication number: 20240101613Abstract: Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, and compositions thereof and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size. In some cases, the reagents are oligomeric particle reagents containing a plurality of binding sites for agents, and thus the one or more agents are multimerized by reversibly binding to the oligomeric particle reagent, e.g., thereby creating a multimerized oligomeric particle reagent, having stimulatory agents multimerized thereon. Also provided are methods for using the oligomeric reagents for incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells such as a population of lymphocytes. In some aspects, the disclosure provides methods and reagents for the stimulation, e.g.Type: ApplicationFiled: November 22, 2023Publication date: March 28, 2024Applicant: Juno Therapeutics GmbHInventors: Thomas SCHMIDT, Christian STEMBERGER, Tom KOWSKI, Ken PRENTICE
-
Patent number: 11913024Abstract: Provided herein are methods for culturing cells, including stimulating or expanding (proliferating), a plurality of cells in a composition of cells such as a population of lymphocytes. In some aspects, provided methods and reagents for the culturing, such as stimulation or expansion (proliferation), of cell populations involve binding of agents to a molecule on the surface of the cells, thereby providing one or more signals to the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for expansion or proliferation or other stimulation of a population of cells, and then such stimulatory agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.Type: GrantFiled: October 20, 2016Date of Patent: February 27, 2024Assignee: Juno Therapeutics GmbHInventors: Lothar Germeroth, Christian Stemberger, Patricia Gräf
-
Patent number: 11866465Abstract: Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, compositions thereof, and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size. In some cases, the reagents are oligomeric particle reagents containing a plurality of binding sites for agents, and thus the one or more agents are multimerized by reversibly binding to the oligomeric particle reagent, e.g., thereby creating a multimerized oligomeric particle reagent, having stimulatory agents multimerized thereon. Also provided are methods for using the oligomeric reagents for incubation or culturing, such as to induce stimulation of expansion, activation, and/or survival, of a composition of cells such as a population of lymphocytes.Type: GrantFiled: April 27, 2018Date of Patent: January 9, 2024Assignee: Juno Therapeutics GmbHInventors: Thomas Schmidt, Christian Stemberger, Tom Kowski, Ken Prentice
-
Publication number: 20230295567Abstract: Provided herein are methods that relate, in some aspects, to the incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells, such as a population of lymphocytes. In some aspects, provided are methods and reagents for the stimulation, e.g., of expansion (proliferation), survival or persistence, activation, costimulation, or other effect, of cell populations that involve binding of agents to a molecule on the surface of the cells, thereby providing one or more signals to the cells. In some cases, the reagents are reagents containing a plurality of binding sites for agents, such as multimerization reagents, and thus the one or more agents are multimerized by reversibly binding to the reagent, e.g., thereby creating a stimulatory reagent (multimerized agent), having stimulatory agents multimerized thereon.Type: ApplicationFiled: October 7, 2022Publication date: September 21, 2023Applicant: Juno Therapeutics GmbHInventors: Lothar Germeroth, Christian Stemberger, Patricia Graf, Keenan Bashour
-
Publication number: 20230190952Abstract: Provided herein are cell surface conjugates containing a cell surface molecule and at least one agent, such as at least one affinity tag, and engineered cells expressing such cell surface conjugates. In some embodiments, the cell surface molecule does not contain an intracellular signaling domain or is not capable of mediating intracellular signaling. In some embodiments, the cells engineered to contain the cell surface conjugate, such as T cells, further contain a genetically engineered recombinant receptor that specifically binds to antigens, such as a chimeric antigen receptor (CAR). Also provided are methods of detecting, identifying, selecting or targeting cells expressing the cell surface conjugates, such as in connection with methods of manufacturing engineered cells or in connection with administration of such cells to subjects, including methods of adoptive cell therapy.Type: ApplicationFiled: October 14, 2022Publication date: June 22, 2023Applicant: Juno Therapeutics GmbHInventors: Lothar GERMEROTH, Christian STEMBERGER
-
Patent number: 11517627Abstract: Provided herein are cell surface conjugates containing a cell surface molecule and at least one agent, such as at least one affinity tag, and engineered cells expressing such cell surface conjugates. In some embodiments, the cell surface molecule does not contain an intracellular signaling domain or is not capable of mediating intracellular signaling. In some embodiments, the cells engineered to contain the cell surface conjugate, such as T cells, further contain a genetically engineered recombinant receptor that specifically binds to antigens, such as a chimeric antigen receptor (CAR). Also provided are methods of detecting, identifying, selecting or targeting cells expressing the cell surface conjugates, such as in connection with methods of manufacturing engineered cells or in connection with administration of such cells to subjects, including methods of adoptive cell therapy.Type: GrantFiled: January 19, 2018Date of Patent: December 6, 2022Assignee: Juno Therapeutics GmbHInventors: Lothar Germeroth, Christian Stemberger
-
Patent number: 11466253Abstract: Provided herein are methods that relate, in some aspects, to the incubation or culturing, such as to induce stimulation of expansion (proliferation), activation, costimulation and/or survival, of a composition of cells, such as a population of lymphocytes. In some aspects, provided are methods and reagents for the stimulation, e.g., of expansion (proliferation), survival or persistence, activation, costimulation, or other effect, of cell populations that involve binding of agents to a molecule on the surface of the cells, thereby providing one or more signals to the cells. In some cases, the reagents are reagents containing a plurality of binding sites for agents, such as multimerization reagents, and thus the one or more agents are multimerized by reversibly binding to the reagent, e.g., thereby creating a stimulatory reagent (multimerized agent), having stimulatory agents multimerized thereon.Type: GrantFiled: October 20, 2016Date of Patent: October 11, 2022Assignee: Juno Therapeutics GmbHInventors: Lothar Germeroth, Christian Stemberger, Patricia Gräf, Keenan Bashour
-
Publication number: 20220243223Abstract: Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.Type: ApplicationFiled: January 18, 2022Publication date: August 4, 2022Applicant: Juno Therapeutics GmbHInventors: Keenan BASHOUR, Semih U. TAREEN
-
Publication number: 20220229054Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.Type: ApplicationFiled: March 29, 2022Publication date: July 21, 2022Applicants: TECHNISCHE UNIVERSITAET MUENCHEN, JUNO THERAPEUTICS GMBHInventors: Magdalena NAUERTH, Dirk BUSCH, Lothar GERMEROTH
-
Publication number: 20220195388Abstract: The present invention relates to in vitro-methods of expanding a population of cells such as lymphocytes, comprising contacting a sample comprising a population of cells with a multimerization reagent. The multimerization reagent has reversibly immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells and optionally, a second agent that provides a co-stimulatory signal. The invention also provides multimerization reagents, kits, arrangements and an apparatus for expanding cells.Type: ApplicationFiled: March 11, 2022Publication date: June 23, 2022Applicant: Juno Therapeutics GmbHInventors: Lothar Germeroth, Christian Stemberger
-
Patent number: 11320431Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.Type: GrantFiled: June 27, 2017Date of Patent: May 3, 2022Assignees: TECHNISCHE UNIVERSITAET MUENCHEN, JUNO THERAPEUTICS GMBHInventors: Magdalena Nauerth, Dirk Busch, Lothar Germeroth
-
Patent number: 11274278Abstract: The present invention relates to in vitro-methods of expanding a population of cells such as lymphocytes, comprising contacting a sample comprising a population of cells with a multimerization reagent. The multimerization reagent has reversibly immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells and optionally, a second agent that provides a co-stimulatory signal. The invention also provides multimerization reagents, kits, arrangements and an apparatus for expanding cells.Type: GrantFiled: April 16, 2015Date of Patent: March 15, 2022Assignee: Juno Therapeutics GmbHInventors: Lothar Germeroth, Christian Stemberger
-
Patent number: 11248238Abstract: Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.Type: GrantFiled: October 20, 2016Date of Patent: February 15, 2022Assignee: Juno Therapeutics GmbHInventors: Keenan Bashour, Semih U. Tareen
-
Publication number: 20220002669Abstract: Provided herein are methods for selecting and stimulating a plurality of cells in a sample of cells using column chromatography, and collecting the cells without using additional steps or reagents to facilitate detachment of the cells from the column. In some aspects, the methods provided herein reduce the time needed to generate a population of selected and stimulated cells useful for genetic engineering, and ultimately, cell therapy, compared to existing methods. Also provided are articles of manufacture and apparatus thereof.Type: ApplicationFiled: October 30, 2019Publication date: January 6, 2022Applicant: Juno Therapeutics GmbHInventors: Lothar GERMEROTH, Christian STEMBERGER, Mateusz Pawel POLTORAK, Thomas SCHMIDT
-
Publication number: 20210032297Abstract: Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, compositions thereof, and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size. In some cases, the reagents are oligomeric particle reagents containing a plurality of binding sites for agents, and thus the one or more agents are multimerized by reversibly binding to the oligomeric particle reagent, e.g., thereby creating a multimerized oligomeric particle reagent, having stimulatory agents multimerized thereon. Also provided are methods for using the oligomeric reagents for incubation or culturing, such as to induce stimulation of expansion, activation, and/or survival, of a composition of cells such as a population of lymphocytes.Type: ApplicationFiled: April 27, 2018Publication date: February 4, 2021Applicant: Juno Therapeutics GmbHInventors: Thomas SCHMIDT, Christian STEMBERGER, Tom KOWSKI, Ken PRENTICE
-
Publication number: 20200316218Abstract: Provided herein are cell surface conjugates containing a cell surface molecule and at least one agent, such as at least one affinity tag, and engineered cells expressing such cell surface conjugates. In some embodiments, the cell surface molecule does not contain an intracellular signaling domain or is not capable of mediating intracellular signaling. In some embodiments, the cells engineered to contain the cell surface conjugate, such as T cells, further contain a genetically engineered recombinant receptor that specifically binds to antigens, such as a chimeric antigen receptor (CAR). Also provided are methods of detecting, identifying, selecting or targeting cells expressing the cell surface conjugates, such as in connection with methods of manufacturing engineered cells or in connection with administration of such cells to subjects, including methods of adoptive cell therapy.Type: ApplicationFiled: January 19, 2018Publication date: October 8, 2020Applicant: Juno Therapeutics GmbHInventors: Lothar GERMEROTH, Christian STEMBERGER
-
Publication number: 20200017880Abstract: Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.Type: ApplicationFiled: October 20, 2016Publication date: January 16, 2020Applicant: Juno Therapeutics GmbHInventors: Keenan BASHOUR, Semih U. TAREEN
-
Publication number: 20190234844Abstract: The present invention relates to the chromatographic isolation of a target cell or another complex biological material, in particular by column chromatography such as affinity chromatography or gel permeation chromatography. The invention employs a receptor binding reagent that binds to a receptor molecule that is located on the surface of a target cell. The invention in general provides novel methods for the traceless isolation of biologic materials such as cells, cell organelles, viruses and the like. The invention also relates to an apparatus for the isolation of cells and other complex biological materials.Type: ApplicationFiled: December 21, 2018Publication date: August 1, 2019Applicant: Juno Therapeutics GmbHInventor: Herbert STADLER
-
Publication number: 20190227061Abstract: The invention relates to a method of determining the dissociation rate constant (koff) of a receptor molecule R on a target cell using a combination of reversible and irreversible cell labeling. The invention further relates to a cell comprising such a receptor molecule R, wherein the cell has bound to it such a combination of cell labeling. The invention further relates to a kit and an apparatus useful in performing the methods of the invention. The invention further relates to a method of isolation a high-avidity T cell.Type: ApplicationFiled: June 27, 2017Publication date: July 25, 2019Applicants: TECHNISCHE UNIVERSITAET MUENCHEN, JUNO THERAPEUTICS GMBHInventors: Magdalena NAUERTH, Dirk BUSCH, Lothar GERMEROTH
-
Publication number: 20190226951Abstract: The present invention relates to the chromatographic isolation of a target cell or another complex biological material, in particular by column chromatography such as affinity chromatography or gel permeation chromatography. The invention employs a receptor binding reagent that binds to a receptor molecule that is located on the surface of a target cell. The invention in general provides novel methods for the traceless isolation of biologic materials such as cells, cell organelles, viruses and the like. The invention also relates to an apparatus for the isolation of cells and other complex biological materials.Type: ApplicationFiled: December 21, 2018Publication date: July 25, 2019Applicant: Juno Therapeutics GmbHInventor: Herbert STADLER